Patents Examined by Matthew Coughlin
  • Patent number: 9937262
    Abstract: The present invention relates to a compound of formula (I): wherein R1 is R3-IPU and R2 is the acyloxy residue of diclofenac or naproxen, and specified by the following structures (A) wherein OH—R3-IPU is selected from (B) and R4 and R5 may be the same or different selected from (C) and salts, solvates and hydrates thereof.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 10, 2018
    Inventor: Claus Selch Larsen
  • Patent number: 9923194
    Abstract: Process for purifying N-alkylpyrrolidones which due to a previous use comprise at least one of the impurities of the formula I or II where R is hydrogen or a C1-C20-alkyl group, wherein a basic compound is added to the N-alkylpyrrolidone to be purified and the temperature of the mixture is at least 80° C. not more than 20 minutes after addition of the basic compound and N-alkylpyrrolidone is distilled off from the mixture obtained.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: March 20, 2018
    Assignee: BASF SE
    Inventors: Rolf Pinkos, Thomas Vogler, Karl Ott
  • Patent number: 9908908
    Abstract: The invention relates to a tenofovir prodrug and pharmaceutical uses thereof. In particular, the invention relates to a compound as shown in general formula (I): and its isomer, pharmaceutically acceptable salt, hydrate or solvate, as well as their uses in preparing drugs for treating viral infectious diseases, especially HIV infection, hepatitis B, or diseases caused by hepatitis B virus, wherein the definition of each substituent in the general formula (I) is as defined in the specification.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: March 6, 2018
    Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.
    Inventors: Fuyao Zhang, Dong Wei
  • Patent number: 9890113
    Abstract: A process for the continuous preparation of adiponitrile by hydrocyanation of 3-pentenenitrile is described, wherein a) 3-pentenenitrile is hydrocyanated to give a reaction output comprising adiponitrile, b) in a work-up 1, a mixture comprising cis-2-methyl-2-butenenitrile and cis-2-pentenenitrile is separated off as overhead product from the reaction output from the reactor R1 in a first distillation apparatus, c) the mixture comprising cis-2-methyl-2-butenenitrile and cis-2-pentenenitrile from step b) is continuously isomerized in the presence of aluminum oxide as catalyst in a reactor R2 to give a product mixture comprising 3-pentenenitrile, d) cis-2-methyl-2-butenenitrile is separated off as overhead product from the reaction output from the reactor R2 in a distillation apparatus in a work-up 2 and discharged.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 13, 2018
    Assignee: BASF SE
    Inventors: Rolf-Hartmuth Fischer, Robert Baumann, Veronika Wloka, Hermann Luyken
  • Patent number: 9889119
    Abstract: Disclosed are methods for the preparation of amorphous N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl]-4-(trifluoromethyl)-benzamide for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. Also disclosed are methods for the preparation of amorphous solid dispersion of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl]-4-(trifluoromethyl)-benzamide.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: February 13, 2018
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. Tyavanagimatt, N K Peter Samuel, Joseph Paz, Ying Tan, Dennis E. Hruby
  • Patent number: 9890125
    Abstract: A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R2CH2MgX to form the corresponding diol product, dehydrating the diol product to the corresponding dialkene; and hydrogenating the diol product to form the corresponding aniline. The 2,6 disubstituted anilines can be used to produce N-Heterocyclic Carbenes (NHCs). The NHCs can find application in various fields such as organic synthesis, catalysis and macromolecular chemistry. Palladium catalysts containing the NHCs are also described.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: February 13, 2018
    Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
    Inventors: Steven P. Nolan, Sebastien Meiries
  • Patent number: 9884814
    Abstract: The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 6, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Christos Tsaklakidis, Markus Klein, Paul Czodrowski
  • Patent number: 9884062
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: February 6, 2018
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Patent number: 9873693
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: January 23, 2018
    Assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • Patent number: 9873677
    Abstract: Provided herein are pharmaceutical compositions, which comprise a 1,2,4-oxadiazole benzoic acid or a pharmaceutically acceptable salt thereof. Further provided herein are certain pharmaceutically acceptable salts of a 1,2,4-oxadiazole benzoic acid and methods for making the same. Further provided herein are methods of treating or preventing a disease associated with a nonsense mutation or a premature stop codon, comprising administering such pharmaceutical compositions or pharmaceutically acceptable salts to a patient having a disease associated with a nonsense mutation or a premature stop codon.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: January 23, 2018
    Assignee: PTC Therapeutics, Inc.
    Inventors: Marla L. Weetall, Ellen Welch, Mandar V. Dali, James Takasugi
  • Patent number: 9862683
    Abstract: Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 9, 2018
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventor: Dongcheng Dai
  • Patent number: 9862706
    Abstract: Imidazolone and pyrazolone derivatives of formula (I) described herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 9, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Carmelida Capaldi, Elisabetta Armani, Andrew Stephen Robert Jennings
  • Patent number: 9862692
    Abstract: Described herein are analogs of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogs having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: January 9, 2018
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • Patent number: 9862698
    Abstract: Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 9, 2018
    Assignee: ADT Pharmaceuticals, Inc.
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • Patent number: 9862730
    Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: January 9, 2018
    Assignees: Bristol-Myers Squibb Company, Universite De Montreal
    Inventors: R. Michael Lawrence, Michael M. Miller, Dietmar Alfred Seiffert, Shoshana L. Posy, Pancras C. Wong, Jacques Banville, Edward H. Ruediger, Daniel H. Deon, Alain Martel, François Tremblay, Julia Guy, Jean-François Lavallée, Marc Gagnon
  • Patent number: 9856266
    Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 2, 2018
    Assignee: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD.
    Inventors: Qingping Zeng, Warren S. Wade, John Bruce Patterson
  • Patent number: 9855274
    Abstract: Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPAR? and may be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 2, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
  • Patent number: 9856213
    Abstract: The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, where in the formula the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at positions 5,6 and 13,14 they may be in cis or in trans orientation, Q stands for a hydroxyl-group and Z stands for a hydroxyl- or oxo-group, R1 and R2 independently represent hydrogen atom or a straight or branched C1-10 alkyl- or aralkyl-group, optionally substituted with —ONO2 group, or an aralkyl- or aryl-group, which contains heteroatom, R3 represents a straight or branched, saturated or unsaturated C4-6 hydrocarbon group, or a C4-10 alkylcycloalkyl- or cycloalkyl-group, or an optionally with alkyl group or halogen atom substituted phenyl-, C7-10 alkylaryl- or hetaryl-group, Y represents (CH2)n group or O atom or S atom, and where n=0-3.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 2, 2018
    Assignee: CHINOIN ZRT
    Inventors: Gábor Havasi, Tibor Kiss, Irén Hortobágyi, Zsuzsanna Kardos, István Lászlófi, Zoltán Bischof, Ádám Bódis
  • Patent number: 9856268
    Abstract: Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: January 2, 2018
    Assignee: G1 Therapeutics, Inc.
    Inventor: Francis Xavier Tavares
  • Patent number: 9855244
    Abstract: O/W-emulsion-type topical pharmaceutical compositions including a retinoid are described. Also described, is a topical pharmaceutical composition including by way of an active pharmaceutical ingredient, a retinoid in a physiologically acceptable composition. Preparation methods and the use of the same in dermatology are also described.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: January 2, 2018
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Agnès Duprat, Claire Mallard